Antibodies Targeting Closely Adjacent or Minimally Overlapping Epitopes Can Displace One Another

Here we describe how real-time label-free biosensors can be used to identify antibodies that compete for closely adjacent or minimally overlapping epitopes on their specific antigen via a mechanism of antibody displacement. By kinetically perturbing one another’s binding towards their antigen via the formation of a transient trimolecular complex, antibodies can displace one another in a fully reversible and dose-dependent manner. Displacements can be readily identified when epitope binning assays are performed in a classical sandwich assay format whereby a solution antibody (analyte) is tested for binding to its antigen that is first captured via an immobilized antibody (ligand) because an inverted sandwiching response is observed when an analyte displaces a ligand, signifying the antigen’s unusually rapid dissociation from its ligand. In addition to classifying antibodies within a panel in terms of their ability to block or sandwich pair with one another, displacement provides a hybrid mechanism of competition. Using high-throughput epitope binning studies we demonstrate that displacements can be observed on any target, if the antibody panel contains appropriate epitope diversity. Unidirectional displacements occurring between disparate-affinity antibodies can generate apparent asymmetries in a cross-blocking experiment, confounding their interpretation. However, examining competition across a wide enough concentration range will often reveal that these displacements are reversible. Displacement provides a gentle and efficient way of eluting antigen from an otherwise high affinity binding partner which can be leveraged in designing reagents or therapeutic antibodies with unique properties.

[1]  J. Pons,et al.  Exploring blocking assays using Octet, ProteOn, and Biacore biosensors. , 2009, Analytical biochemistry.

[2]  Adam R Miles,et al.  Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platforms , 2015, mAbs.

[3]  Mingde Zhu,et al.  Kinetic analysis of a high-affinity antibody/antigen interaction performed by multiple Biacore users. , 2006, Analytical biochemistry.

[4]  Adam R Miles,et al.  High-Throughput Epitope Binning Assays on Label-Free Array-Based Biosensors Can Yield Exquisite Epitope Discrimination That Facilitates the Selection of Monoclonal Antibodies with Functional Activity , 2014, PloS one.

[5]  R. Darling,et al.  Kinetic exclusion assay technology: characterization of molecular interactions. , 2004, Assay and drug development technologies.

[6]  A. Sivasubramanian,et al.  Broad epitope coverage of a human in vitro antibody library , 2016, mAbs.

[7]  Ana Cauerhff,et al.  Structural mechanism for affinity maturation of an anti-lysozyme antibody. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[8]  T. Knöchel,et al.  Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. , 2008, Cancer cell.

[9]  P. Jeffrey,et al.  Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. , 2005, Cancer cell.

[10]  L. Wyns,et al.  Degenerate interfaces in antigen-antibody complexes. , 2001, Journal of molecular biology.

[11]  R. Palfree,et al.  Isolation and sequence of the granulin precursor cDNA from human bone marrow reveals tandem cysteine-rich granulin domains. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[12]  L. Wyns,et al.  Strong in Vivo Maturation Compensates for Structurally Restricted H3 Loops in Antibody Repertoires* , 2005, Journal of Biological Chemistry.

[13]  M. Sliwkowski,et al.  A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. , 2011, Cancer cell.

[14]  David G Myszka,et al.  Exploring "one-shot" kinetics and small molecule analysis using the ProteOn XPR36 array biosensor. , 2006, Analytical biochemistry.

[15]  A. Rajpal,et al.  Determining the Binding Affinity of Therapeutic Monoclonal Antibodies towards Their Native Unpurified Antigens in Human Serum , 2013, PloS one.

[16]  T. Bhat,et al.  Three-dimensional structure of a heteroclitic antigen-antibody cross-reaction complex. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Myszka,et al.  Improving biosensor analysis , 1999, Journal of molecular recognition : JMR.

[18]  P. Kussie,et al.  Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. , 2008, Structure.